Press "Enter" to skip to content

Poziotinib Shows Promise in Hard-to-Treat NSCLC Exon 20 Mutations – OncLive

admin 0

Poziotinib Shows Promise in Hard-to-Treat NSCLC Exon 20 Mutations  OncLive

Poziotinib, a novel drug that targets relatively uncommon EGFR and HER2 exon 20 insertion mutations, is being tested in a biomarker-driven trial of patients with …

“lung cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *